Dr Dennis Langer: Dr Reddy’s Laboratories announced that Dr Dennis Langer has joined the company as president, North American operations. Dr Langer will be responsible for the management of the company’s North American operations and will be based at the company’s offices in New Jersey.
A native of New York, Dr Langer has a JD (cum laude) from Harvard Law School, an MD from Georgetown University School of Medicine, and a BA in biology from Columbia University.
Dr Langer joins Dr Reddy’s from GlaxoSmithkline, where he held various management positions since 1994. Most recently, he served as senior vice president, Project and Portfolio Management, Research and Development. In this position, he was responsible for worldwide project and portfolio management activities for all research and development assets, for all therapeutic areas.
In addition, he was also leading the alliance and joint venture management function. Prior to that, Dr Langer held a variety of management positions involving increasingly responsibility in the areas of global product development strategy, healthcare services and business strategy with GlaxoSmithkline. He has also served as the CEO of Neose Pharmaceuticals and held various positions at GD Searle, Abbott and Eli Lilly. Dr Langer was also chief resident in psychiatry at Yale University School of Medicine and held clinical fellowships in psychiatry at Harvard Medical School and George Washington University School of Medicine.
Dara B Patel has taken over charge as Secretary-General of Indian Drug Manufacturers' Association
(IDMA) from September 1, 2002. He has earlier worked with Pharma majors such as Wockhardt and
Barbhaiya, former vice president and worldwide Head of the Department of Metabolism and Pharmacokinetics in the Division of Discovery and Early Development, at Bristol Myers Squibb (BMS) Pharmaceutical Research Institute in Princeton, New Jersey, USA has taken charge as the head of Research & Development, at Ranbaxy with effect from August 1, 2002.
Dr. Barbhaiya has over 25 years of corporate and academic experience covering a broad spectrum of pharmaceutical sciences. During his tenure at BMS, he played a key role in introducing 'developability' as a key criterion for selecting drug candidates for development which contributed significantly in making BMS an industry leader in rapid IND filings. He was instrumental in formalising strategies for life cycle management of a number of marketed products, the more recent one, the introduction of once a day formulation and a combination product of metformin. Dr. Barbhaiya has also successfully led a number of projects through NDAs some of which have become important drugs for BMS.
A doctorate in clinical pharmacology from the University of London, UK, he has been conferred with prestigious awards like the AAPS Fellow award from the American Association of Pharmacological Scientists 1993, the Ranbaxy award for excellence in Pharmaceutical Research, Ranbaxy Foundation, India 1993, and Meritorious Manuscript Award from the American Association of Pharmaceutical Scientists, 1998.
Saxena, former president and CEO of Reddy US Therapeutics Inc. (Reddy US), a biopharmaceutical company and subsidiary of Dr. Reddy's based in Atlanta, US, has been appointed as the Chief Scientific Officer (CSO) of Dr. Reddy's Laboratories. He is to oversee global R&D activities of Dr.Reddy's.
Dr. Saxena joined Dr. Reddy's in early 2000 as the head of Reddy US. He has been instrumental in building a top-notch team of scientists and in setting up a discovery programme focussed on novel therapeutics that address unmet medical needs in diabetes, inflammation and cardiovascular disease.
Dr. Saxena has been in the pharmaceutical/biotech industry for over a decade. Prior to joining Dr. Reddy's, he held several key positions at AtheroGenics, Inc., a publicly traded biopharmaceutical company located in Alpharetta, Georgia and Parke-Davis Research Division, Ann Arbor, Michigan. He has been an invited as speaker at several national and international meetings and is currently on the editorial board of two drug discovery related Journals and routinely reviews articles for research journals. He is an elected fellow of the Council on Arteriosclerosis, American Heart Association since 1991. He has over 45 full publications in peer-reviewed journals. He is also an inventor and has to his credit several patents related to cardiovascular disease and inflammation. He received his PhD from Memorial University of Newfoundland in Canada and was a post-doctoral fellow at Columbia University in New York.
Dr. Norton P Peet,
former vice president of Discovery Alliances, part of ArQule, a Woburn; Massachusetts based drug Discovery Company, joins as chief executive officer in Aurigene Discovery Technologies, a wholly-owned subsidiary of Dr. Reddy's Laboratories, Hyderabad with effect from April 1, 2002.
In ArQule, Dr. Peet was responsible in managing external alliances and building an internal drug discovery organization. A distinguished scientist, he was the Head of Medicinal Chemistry at Aventis, a leading multinational pharmaceutical company. Dr. Peet, who serves on several editorial boards, e is a scientific advisor for Drug Discovery Technology and for the IBC USA Conferences Board.
Agrawal, joint managing director of Ajanta Pharma has been appointed as the chairman of India Mauritius Joint Business Council for two years. He has been appointed by FICCI and ASSCHAM as Chairman of India Kyrghyzstan Joint Business Council and India -Peru Joint Business Council.
Agrawal, a graduate in science is a man of vision and strong determination. He has associated with Ajanta Pharma for the last twenty-five years of its existence. He has contributed immensely to the nourishment and consolidation of the company, which has established a name in the domestic healthcare sector with a range of healthcare products, pharmaceuticals and bulk drugs. Ajanta Pharma has set up joint ventures in Mauritius, Uzbekistan, Turkmenistan, Tajikistan, Kazakhstan and Kyrghyzstan to manufacture pharmaceuticals and healthcare products with its in-house technology. He is also a patron of fine arts.
Atul Malhotra has joined Ranbaxy Laboratories Ltd as Head-Global OTC & Regional Director (Middle East). An electrical engineer from IIT
Kanpur, Malhotra has managed various businesses such as animal feed, detergents, personal products, foods and beverages in a career spanning 24 years with Hindustan Lever.
Sanjeev Dani who has served as Marketing Director- Xian Janssen, China and Vice President - Sales and Marketing of India operations of Johnson & Johnson
(Janssen-Cilag Pharmaceuticals) has joined RLL as Director-Pharma Marketing. In his nearly 18 years of experience, he has also worked for Searle India Ltd. and Lupin Laboratories Ltd.
Lalit Ahluwalia has joined the company yesterday as Director-Business Finance Ahluwalia brings with him work experience of 24 years with ITC Limited, Pepsi Foods Limited and Gillette India Limited. Ahluwalia holds a Bachelor's Degree in Commerce from St.Xaviers College, Calcutta and is an Associate member of the Institute of Chartered Management Accountants, England.
Udai Upendra has joined the Company as Vice-President-Global Human Resources. An alumni of
XLRI, Upendra brings with him over 24 years of experience with organisations such as Godfrey Phillips, Hindustan Lever and Colgate Palmoliveo
B. B. Sharma
former director, Export Credit Guarantee Corporation (ECGC), and senior officer in the Maharashtra I A S cadre, has been appointed commissioner, Food and Drug Administration, Maharashtra. Sharma takes over the post after the exit of B K Agarwal, who was shifted to General Administration, Government of Maharashtra, in the first week of this month.
Sharma is currently a senior official in the Maharashtra Civil Service in the rank of Additional Secretary. The new commissioner, who was with ECGC prior to this appointment, is learnt to be new to the field of drug control administration even as the post is expected to have a great responsibility as far as the fresh stipulations in the drug trade as well as quality production standards are concerned. While speaking to pharmabiz.com, on the first day in his new post, Sharma said that he is currently in the process of going through the files and case studies to have a better understanding of the area.
Former commissioner of the state FDA B K Agarwal was transferred to the State General Administration with immediate effect. Agarwal, who has taken charge as additional chief secretary, General Administration, Government of Maharashtra, on 31st March, was also asked to take additional charge of State FDA since the post was vacant till the appointment of Sharma.
B K Agarwal IAS, who served almost two years in the position of commissioner, FDA, Maharashtra, was appointed to this post on 16th June 1999. During the two years tenure as commissioner- FDA, Agarwal was instrumental in implementation of various new drug control rules in the state and in few controversies in connection with drug approvals and related issues.
Karen Katen has been appointed as the president of the Pfizer Pharmaceutical Group and executive vice-president of Pfizer Inc to oversee the global operation. According to a report, Karen will also retain her duties as president of the US pharmaceutical operations while the new assignment would become effective from April 1 onwards.
G. Dakshinamurthy has taken over as new Director, Drug Control Administration, Tamil Nadu. Prior to the present assignment, he was the Deputy Director (Enforcement Wing) based in
Chennai. Born in Salem in 1944, he joined the Department in 1971 as a drug inspector. In 1993, he was posted as the Assistant Director, Coimbatore zone, a post, which he held till 1997, whereafter he was posted as the Assistant Director (Madurai zone). In 1999, he was made the Assistant Director, Vellore zone.
Dakshinamurthy has to his credit many successful raids that resulted in closure or cancelling of licences.
Kishore Chokhani was elected chairman of the Basic Chemicals, Pharmaceuticals and Cosmetics Export Promotion Council (Chemexcil) for the year 2000-2001. Chokhani, a B.Com. and LLB from the University of Mumbai, started his career as a garment exporter and has been in the field of pharmaceuticals exports for the last 14 years. He is the managing director of Euro Asia Trans Continental, which is involved in exporting pharmaceuticals, flavours and food colours. The company has bagged several awards for excellence in exports. Chokhani has travelled all over the world and has been involved in marketing of new products to new markets and has addressed various conferences on the Indian pharmaceutical industry on behalf of Chemexcil.
Chirayu R Amin,
the chairman and managing director of pharma major Alembic Ltd, assumed the office of president, Federation of Indian Chambers of Commerce and Industry (Ficci) for 2000-01 at the conclusion of the Chamber's 73rd session. Amin, who has been a senior member of the executive committee of Ficci for several years, earlier held posts like chairman Ficci committees on management and environment besides heading the Indo-Italian and Indo-Spanish joint business councils.
Executive Diary >>